Isolated HbA1c identifies a different subgroup of individuals with type 2 diabetes compared to fasting or post-challenge glucose in Asian Indians: The CARRS and MASALA studies. by Gujral, UP et al.
Accepted Manuscript
Isolated HbA1c identifies a different subgroup of individuals with type 2 dia-
betes compared to fasting or post-challenge glucose in Asian Indians: The
CARRS and MASALA Studies
U.P. Gujral, D. Prabhakaran, R. Pradeepa, N.R. Kandula, D. Kondal, M. Deepa,
N.A. Zakai, R.M. Anjana, G. Rautela, V. Mohan, K.M.V. Narayan, N. Tandon,
A.M. Kanaya
PII: S0168-8227(18)31664-4
DOI: https://doi.org/10.1016/j.diabres.2019.05.026
Reference: DIAB 7747
To appear in: Diabetes Research and Clinical Practice
Received Date: 8 November 2018
Revised Date: 15 May 2019
Accepted Date: 22 May 2019
Please cite this article as: U.P. Gujral, D. Prabhakaran, R. Pradeepa, N.R. Kandula, D. Kondal, M. Deepa, N.A.
Zakai, R.M. Anjana, G. Rautela, V. Mohan, K.M.V. Narayan, N. Tandon, A.M. Kanaya, Isolated HbA1c identifies
a different subgroup of individuals with type 2 diabetes compared to fasting or post-challenge glucose in Asian
Indians: The CARRS and MASALA Studies, Diabetes Research and Clinical Practice (2019), doi: https://doi.org/
10.1016/j.diabres.2019.05.026
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
1
Isolated HbA1c identifies a different subgroup of individuals with type 2 diabetes compared to 
fasting or post-challenge glucose in Asian Indians: The CARRS and MASALA Studies
UP Gujrala, D Prabhakaranb,c, R Pradeepad, NR Kandulae, D Kondalb, M Deepad, NA Zakaif, RM 
Anjanad, G Rautelab, V Mohand, KMV Narayana,g, N Tandonb,h, AM Kanaya, MDi
aEmory Global Diabetes Research Center, Hubert Department of Global Health, Rollins School 
of Public Health, 1518 Clifton Road NE. Room 7040 N, Emory University, Atlanta, GA, USA, 
ugujral@emory.edu, knaraya@emory.edu 
bPublic Health Foundation of India, Unit No. 316 situated on 3rd Floor, 
Rectangle -1 Building, Plot No. D-4, District Centre Saket, New Delhi, India
dprabhakaran@ccdcindia.org, dimple.kondal@phfi.org, garima@ccdcindia.org, 
nikhil_tandon@hotmail.com
cLondon School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom
dprabhakaran@ccdcindia.org
dMadras Diabetes Research Foundation & Dr. Mohan’s Diabetes Specialities Centre, WHO 
Collaborating Centre for Non-communicable Diseases, Prevention & Control, ICMR Centre for 
Advanced Research on Diabetes, Chennai, India guhapradeepa@gmail.com, 
deepa.mohan1@gmail.com, dranjana@drmohans.com, drmohans@diabetes.ind.in  
eDivision of General Internal Medicine, Northwestern University Feinberg School of Medicine, 
750 N Lake Shore Drive, 6th Floor, Chicago, IL, USA, Namratha.Kandula@nm.org
fDepartment of Medicine, Department of Pathology & Laboratory Medicine, Larner College of 
Medicine at the University of Vermont, 89 Beaumont Avenue, Courtyard at Given S269 Burlington 
VT, USA, neil.zakai@uvm.edu
gDepartment of Medicine, School of Medicine, 201 Dowman Drive Emory University, Atlanta, GA, 
USA, knaraya@emory.edu
hDepartment of Endocrinology and Metabolism, All Indian Institute of Medical Sciences, Ansari 
Nagar, New Delhi, India, nikhil_tandon@hotmail.com 
iDivision of General Internal Medicine, University of California, San Francisco, San Francisco, 
CA, USA., Alka.Kanaya@ucsf.edu
Corresponding Author:  
Unjali Gujral, MPH, PhD
c/o Emory University, 
Rollins School of Public Health
1518 Clifton Road, CNR 7040-L
Atlanta, GA  30322
Phone: (626) 589-8512
E-mail: ugujral@emory.edu
Word Count:  Abstract: 200; Main Text: 3,964; Numbers of Tables/Figures: 4
  
2
Abstract  
Aims: Guidelines recommend hemoglobin A1c (HbA1c) as a diagnostic test for type 2 diabetes, 
but its accuracy may differ in certain ethnic groups. 
Methods: The prevalence of type 2 diabetes by HbA1c, fasting glucose, and 2 hour glucose was 
compared in 3,016 participants from Chennai and Delhi, India from the CARRS-2 Study to 757 
Indians in the U.S. from the MASALA Study. Type 2 diabetes was defined as fasting glucose ≥ 
7.0 mmol/L, 2-hr glucose ≥ 11.1 mmol/L, or HbA1c ≥ 6.5%. Isolated HbA1c diabetes was 
defined as HbA1c ≥ 6.5% with fasting glucose <7.0 mmol/L and 2hr glucose < 11.1 mmol/L.        
Results: The age, sex, and BMI adjusted prevalence of diabetes by isolated HbA1c was 2.9% 
(95% CI: 2.2-4.0), 3.1% (95% CI: 2.3-4.1), and 0.8% (95% CI: 0.4-1.8) in CARRS-Chennai, 
CARRS-Delhi, and MASALA, respectively. The proportion of diabetes diagnosed by isolated 
HbA1c was 19.4%, 26.8%, and 10.8% in CARRS-Chennai, CARRS-Delhi, and MASALA 
respectively. In CARRS-2, individuals with type 2 diabetes by isolated HbA1c milder cardio-
metabolic risk than those diagnosed by fasting or 2-hour measures.
Conclusions: In Asian Indians, the use of HbA1c for type 2 diabetes diagnosis could result in a 
higher prevalence. HbA1c may identify a subset of individuals with milder glucose intolerance. 
Keywords:  Type 2 Diabetes, HbA1c, diagnostic criteria
  
3
Introduction
Measurement of fasting plasma glucose (FPG) and/or 2-hour post challenge glucose (2hPG) 
levels have traditionally been the cornerstone of the diagnosis of diabetes mellitus (DM) [1].  In 
2009 an international expert committee recommended the use of HbA1c as an additional 
diagnostic criterion for DM [2] and it is now recommended as a diagnostic tool by both the 
American Diabetes Association and the World Health Organization [3,4]. While HbA1c is now 
often used in clinical practice, it is possible that the pathophysiological mechanisms of type 2 
diabetes development may differ in those identified by HbA1c compared to fasting or 2-hour 
glucose measures, and its accuracy as a diagnostic tool has not been well tested in populations 
such as Asian Indians, a group with particularly high type 2 diabetes risk [5,6]. We aimed to 
compare HbA1c as a diagnostic tool with fasting plasma glucose and 2-hour post-challenge 
glucose measurements in assessing the prevalence of type 2 diabetes in two South Asian 
populations. One population was from two geographic centers in India (from the Center for 
cArdio-metabolic Risk Reduction in South Asia (CARRS-2) study) [7], and the other from two 
geographic centers in the United States (from the Mediators of Atherosclerosis in South Asians 
Living in America (MASALA) study) [8].
Methods
We conducted a cross-sectional analysis of data from two large, population-based cohorts, one in 
India and one in the United States.  In total, 1,568 participants living in Chennai, India and 1,448 
participants living in New Delhi, India from the CARRS-2 Study were compared with 757 Asian 
Indian immigrants in the MASALA Study. 
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Description of Participants 
The CARRS-2 Study
In brief, CARRS-2 is a multi-site cross-sectional study recruiting participants from the cities of 
Chennai and New Delhi in India and Karachi in Pakistan.  Study design and recruitment for 
CARRS-2 was methodically akin to that of CARRS-1 which was conducted in 2010-2011 [7]. 
For the purposes of this study we analyzed data only from the Chennai and New Delhi sites in 
order to limit our analysis to Asian Indians. This was done in order to remain in accordance with 
MASALA which had very few participants with origins from Pakistan.  Recruitment occurred 
between September 2014 and March 2016. A multi-stage random sampling technique was used 
to select households for participation in order to be representative of Delhi and Chennai. In order 
to reduce selection bias, two adults, one male and one female, aged 20 years or older were 
selected from each household. In households with more than two eligible members, the “Kish 
method” was applied to determine enrollment [9]. Recruitment, enrollment, and data collection 
were collected through three visits to each participant’s place of residence. In order to maintain 
valid comparisons with MASALA, we excluded participants who were younger than age 40 
and/or who had existing cardiovascular disease as ascertained through self-report. Pregnant 
women and bed-ridden individuals were excluded from study enrollment [7].  
Demographic and behavioral information including language use, medical history, 
current medication use, and use of alcohol and tobacco were obtained using standardized 
questionnaires administered by trained interviewers. Physical activity was assessed using the 
Global Physical Activity Questionnaire (GPAQ). Blood pressure was assessed using an 
electronic sphygmomanometer (Omron HEM-7080 and HEM-7080IT-E; Omron Corporation, 
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Tokyo, Japan). Three seated measurements were taken, and an average of the three was used to 
assess systolic and diastolic blood pressure. After an 8-12 hour overnight fast, a 75g oral 
glucose tolerance test (OGTT) was administered to participants without previously diagnosed 
diabetes who were willing and able to participate. Blood samples were obtained from a 
peripheral vein just before glucose ingestion (fasting) and at 30 minutes and 2-hours post 
glucose challenge for plasma glucose measurements. The samples were transported from field 
sites in cold chain to the laboratories for analysis. Both accredited laboratories in Delhi and 
Chennai participated in a Randox International Quality Assessment Scheme (RIQAS) that 
standardized findings to a central laboratory at the All India Institute of Medical Sciences 
(AIIMS) in Delhi. Blood samples were analyzed on the same day as they were collected. For 
the three cities together (including Karachi, Pakistan), response rates were 94.7% for 
questionnaire completion and 84.3% for bio-specimens. Total cholesterol was measured by 
enzymatic colorometric cholesterol oxidase peroxidase method, high-density lipoprotein 
cholesterol by direct method, and triglycerides by enzymatic methods using Roche/Boehringer-
Mannheim Diagnostics. Low-density lipoprotein cholesterol cholesterol was calculated using 
Friedewald’s formula. 
Plasma glucose was measured by hexokinase/kinetic method, and glycated hemoglobin 
(HbA1c) was measured by high performance liquid chromatography (HPLC). Insulin was 
measured using the electro chemiluminescence immune assay (ECLIA).  Participant weight was 
measured using body composition analyzers (Tanita BC-601), and height was measured using a 
portable stadiometer (SECA-213). BMI was calculated as weight in kilograms divided by height 
in meters squared.  Waist circumference was measured using a non-stretch measuring tape 
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(SECA-201) at the site of maximum circumference halfway between the lower ribs and the 
anterior superior iliac spine. 
MASALA Study 
 The design, sampling strategy, recruitment, enrollment, and both questionnaire and examination 
components of the MASALA study have been described previously [8]. Briefly, MASALA is a 
community-based sample of South Asian Americans living in the greater San Francisco Bay and 
Chicago areas. Participants were aged 40-84 years, and are without previously known cardio-
vascular disease. Recruitment occurred between October 2010 and March 2013. All participants 
were screened by telephone and were invited to either the University of California, San 
Francisco, or the Northwestern University clinical field center for a 6-hour baseline clinical 
examination [8].                  
South Asian ethnicity was self-reported and defined as having 3 or more grandparents 
born in either India, Pakistan, Nepal, Bangladesh, or Sri Lanka. However, for the purposes of 
this study in order to remain in accordance with CARRS, we limited our sample to the 757 
individuals who were born in India specifically. Individuals with previous diagnosis of heart 
attack, stroke, transient ischemic attack, heart failure, angina, nitroglycerin medication use, any 
prior cardiovascular procedures, current arterial fibrillation, cancer treatment, shortened life 
expectancy, impaired cognition, plans to move out of the geographic area of the study site in the 
next five years, living in a nursing home, or weight > 300 pounds were excluded from study 
enrollment [8].
Demographic and behavioral information including language use, medical history, 
current medication use, and use of alcohol and tobacco were obtained using standardized 
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questionnaires administered by trained interviewers. Physical activity was assessed using the 
Typical Week’s Physical Activity Questionnaire [10]. After a 5-minute seated rest, blood 
pressure was assessed using an automated blood pressure machine (V100 Vital Sign Monitor; 
GE Healthcare, Fairfield, CT, USA). Three seated measurements were taken, and an average of 
the last two readings was used to assess systolic and diastolic blood pressure. After at least a 9 
hour overnight fast, a 75g oral glucose load was administered to participants without previously 
diagnosed diabetes who were willing to participate. Blood samples were obtained from a 
peripheral vein just before glucose ingestion (fasting) and at 30 minutes and 2-hours post glucose 
challenge. Plasma glucose was measured using the hexokinase method. Fasting serum samples 
were batched for insulin measured by the sandwich immunoassay method (Roche Elecys 2010; 
Roche Diagnostics, Indianapolis, IN). HbA1c was measured using the immunoturbidimetry 
assay. Total cholesterol, triglycerides, and high density lipoprotein cholesterol were analyzed 
using enzymatic methods and low-density lipoprotein cholesterol was calculated using the 
Friedewald equation. 
Participant weight was measured using a standing balance beam scale or digital weighing 
scale, and height was measured using a stadiometer.  BMI was calculated as weight in kilograms 
divided by height in meters squared. Waist circumference was measured by trained study staff 
using a non-stretch tape measure at the site of maximum circumference halfway between the 
lower ribs and the anterior superior iliac spine. Two measures were taken and the average was 
used for analysis. Computed tomography (CT) scans of the abdomen (Philips Medical Systems, 
Andover, MA; Toshiba Medical Systems, Tustin, CA; Siemens Medical Solution Malvern, PA) 
were used to assess visceral, subcutaneous, and intermuscular fat mass. Non-contrast cardiac CT 
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images using a cardiac-gated CT scanner (UCSF: Phillips 16D scanner or Toshiba MSD 
Aquillion 64; NWU: Seimens Sensation Cardiac 64 Scanner) were obtained to assess pericardial 
fat volume and hepatic fat attenuation.
Informed consent and ethics committee approval 
The CARRS-2 study was approved by the Institutional Review Boards of the Public 
Health Foundation of India, New Delhi, All India Institute of Medical Sciences, New Delhi, 
Madras Diabetes Research Foundation, Chennai, India, Aga Khan University, Karachi, Pakistan, 
and Emory University, Atlanta, USA [7].  The MASALA Study was approved by both the 
Univeristy of California San Francisco and Northwestern University Institutional Review Boards 
[8].  
Definition of Type 2 Diabetes 
In order to assess the prevalence of newly diagnosed type 2 diabetes by glycemic measure, we 
excluded individuals with a previously known diagnosis of diabetes who were taking any 
glucose lowering medication (n= 1,728 for CARRS and n= 124 for MASALA).  We further 
excluded those who were missing fasting glucose, 2-hour glucose or HbA1c data from the 
CARRS-2 (n=6,880) and the MASALA (n=28) cohorts. A new laboratory diagnosis of type 2 
diabetes was made if fasting glucose ≥ 7.0 mmol/L, 2-hr post challenge glucose ≥ 11.1 mmol/L 
and/or HbA1c ≥ 6.5%.  Isolated fasting type 2 diabetes was defined as fasting glucose ≥ 7.0 
mmol/L; HbA1c < 6.5%; and 2hr glucose < 11.1 mmol/L. Isolated 2-hr post challenge type 2 
diabetes was defined as 2hr glucose ≥ 11.0 mmol/L; fasting glucose < 7.0 mmol/L, HbA1c < 
6.5%. Isolated HbA1c type 2 diabetes was defined as HbA1c ≥ 6.5%; fasting glucose <7.0 
mmol/L and 2hr glucose < 11.1 mmol/L [3].  Normal glucose tolerance was defined as those 
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participants who had both fasting plasma glucose <5.6 mmol/l and a 2 hour post-challenge 
glucose <7.8 mmol/l, as well as HbA1c < 5.7% [3].   
Calculations
Beta-cell function was estimated by the oral disposition index (DIo) and was calculated as 
(ΔI0-30/ΔG0-30)*(1/fasting insulin) [11], and by HOMA-β, [20*I0(µIU/ml) / G0 (mmol/l)- 3.5] 
[12]. HOMA-IR was used to measure insulin resistance and calculated as [I0(µIU/ml) * G0 
(mmol/l)/22.5] [12].  Given that fasting and 30-minute insulin measures were not available for 
the CARRS-2 Chennai site, we calculated disposition index, HOMA-β and HOMA-IR for the 
CARRS-2 Delhi and MASALA sites only.   
Statistical Analysis
Prevalence values and 95% confidence intervals were estimated by glucose measure and 
study site. Participant characteristics of those with type 2 diabetes were stratified by glycemic 
measure and study site and were compared by study using chi-squared test or ANOVA as 
appropriate. The non-normally distributed variables were log transformed. The effect of isolated 
HbA1c on the odds of type 2 diabetes compared to normal glucose tolerance or prediabetes was 
assessed using standardized logistic regression. Initially, a regression model was created to 
compare the odds of having diabetes diagnosed by isolated HbA1c compared to no diabetes after 
adjusting for age and sex. Subsequent multivariable models were then created to adjust for 
additional variables including education physical activity smoking status, body mass index, 
blood pressure, cholesterol triglycerides, insulin resistance, beta-cell function, and vegetarian 
diet. In MASALA, an additional model was run to adjust for adiponectin, resistin, and ectopic 
fat. All analyses were performed using SAS Version 9.4 (SAS Institute, Cary, NC).
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RESULTS
Table 1 provides details on the prevalence of type 2 diabetes by diagnostic criterion and 
study site.  The age, sex, and BMI adjusted prevalence of any newly diagnosed type 2 diabetes 
was 18.2% (95% CI: 15.8-20.9) in CARRS-2 Chennai, 14.0% (95% CI: 12.0-16.4) in CARRS-2 
Delhi, and 12.5% (95% CI: 9.6-16.4) in MASALA. If using isolated elevated HbA1c to define 
type 2 diabetes, the age, sex, and BMI adjusted prevalence was 2.9% (95% CI: 2.2-4.0), 3.1% 
(95% CI: 2.3-4.1), and 0.8% (95% CI: 0.4-1.8) in CARRS-Chennai, CARRS-Delhi, and 
MASALA, respectively.  In both sites in India, the prevalence of type 2 diabetes diagnosed by 
HbA1c was greater than the prevalence as diagnosed by fasting glucose or 2-hr post challenge 
glucose. Figure 1 provides details about the proportion of diabetes diagnosed by each glycemic 
measure by study site. In CARRS-2 Chennai, 19.4% of type 2 diabetes cases were diagnosed by 
isolated HbA1c, while 26.8% of type 2 diabetes cases were diagnosed by isolated HbA1c in 
CARRS-2 Delhi.  In MASALA, 10.8% of the new type 2 diabetes cases were diagnosed by 
isolated elevated HbA1c.   
Participant characteristics by glycemic status and study population are shown in Tables 2 
and 3.  In CARRS-2, compared to those with type 2 diabetes diagnosed by either the fasting or 2-
hour glucose criteria, those with type 2 diabetes as diagnosed solely by HbA1c were significantly 
older, with a greater proportion consuming a vegetarian diet. They also had lower mean systolic 
and diastolic blood pressure, fasting glucose, 30-minute glucose, 2-hour post challenge glucose, 
HbA1c value and triglycerides.  In a subset of individuals from the Delhi site only, those with 
type 2 diabetes diagnosed by isolated HbA1c had significantly lower HOMA-IR, higher HOMA-
β, and higher mean disposition index compared to those with type 2 diabetes diagnosed by either 
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of the glucose measures. We compared the characteristics of type 2 diabetes diagnosed by 
isolated elevated HbA1c to type 2 diabetes diagnosed by HbA1c and with either glucose criterion 
in CARRS-2 participants (Supplemental Table 1). Those diagnosed by HbA1c and a glucose 
criterion more closely resembled those diagnosed by fasting or 2-hour glucose measures 
compared to those diagnosed by isolated elevated HbA1c.   
In MASALA (Table 3), we compared the clinical characteristics of those with type 2 
diabetes by either the fasting or 2-hour glucose criteria to those with type 2 diabetes as diagnosed 
by isolated HbA1c. Those with type 2 diabetes classified by isolated HbA1c had a significantly  
lower mean fasting glucose, 30-minute post-challenge glucose, 2-hour glucose, , lower 
cholesterol, and greater mean HOMA-β and resistin than those diagnosed by fasting or 2-hour 
measures. HOMA-IR was significantly lower in those with type 2 diabetes diagnosed by isolated 
HbA1c compared to those diagnosed by fasting glucose, however it was not significantly 
different in those diagnosed by 2-hour glucose. Fasting insulin was significantly higher in those 
with type 2 diabetes diagnosed by fasting glucose, but was not significantly different  in those 
diagnosed by 2-hour glucose compared to those diagnosed by HbA1c. There were no significant 
differences in ectopic fat measures between those with type 2 diabetes diagnosed by isolated 
HbA1c compared to fasting or 2-hour glucose measures. As with CARRS, those diagnosed by 
HbA1c and another glucose criterion in MASALA more closely resembled those diagnosed by 
fasting or 2-hour glucose measures compared to those diagnosed by isolated HbA1c. 
(Supplemental Table 2)
In the CARRS-2 study, using backwards stepwise regression models including age, sex, 
education, physical activity, smoking status, vegetarian diet, BMI, waist circumference, systolic 
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and diastolic blood pressure, and HDL, LDL, and triglycerides, only age (OR 1.03; 95% CI: 
1.01, 1.06) and waist circumference (per cm, OR 1.02; 95% CI: 1.00, 1.04) were significantly 
associated with type 2 diabetes diagnosed by isolated HbA1c compared to no diabetes. In a 
subset of individuals from the Delhi site only, after additional adjustment for HOMA-IR, 
HOMA-β, and Disposition Index, only waist circumference (OR 1.03; 95% CI: 1.01, 1.06), 
HOMA-IR (OR 1.31; 95% CI: 1.06, 1.62), and HOMA-β (OR 0.99; 95% CI: 0.98, 0.99) were 
associated with having type 2 diabetes diagnosed by HbA1c as opposed to not having diabetes.     
Despite the small sample with isolated elevated HbA1c in MASALA (n=8), waist 
circumference (OR 1.09; 95% CI: 1.01, 1.68), HOMA-IR (OR: 2.30, 95% CI: 1.13, 4.67), and 
HOMA-β (OR 0.97; 95% CI: 0.94, 0.99) were significantly associated with the odds of having 
type 2 diabetes diagnosed by HbA1c after adjusting for all other relevant covariates in the model. 
DISCUSSION
In two population-based studies of Asian Indians living in India and the United States, we 
found that the prevalence of type 2 diabetes was highest when diagnosed by HbA1c, followed by 
2-hour post challenge glucose, and then fasting glucose measures in those living in India, and 
was highest by 2-hour post challenge glucose in those living in the United States. We also found 
that between 1.3% to 3.5% of Asian Indians met type 2 diabetes criteria solely due to an elevated 
HbA1c.   
The prevalence of type 2 diabetes diagnosed by isolated elevated HbA1c varies by 
race/ethnicity, and may be higher in populations of Asian descent. In our two Asian Indian 
populations, we found a prevalence between 1.3 to 3.5%.  Studies in other Asian populations 
also found a prevalence of isolated HbA1c diagnosed type 2 diabetes, similar to the range we 
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found in our study. A study from Korea found a type 2 diabetes prevalence of 2.1% when using 
isolated HbA1c as the diagnostic criterion [13], while a study in Filipino Americans, Japanese 
Americans, and Native Hawaiians noted a type 2 diabetes prevalence of 2.7% by isolated HbA1c 
[14].  
The results of our study are similar to those of a previous study comparing the prevalence 
of type 2 diabetes by glycemic measures in Asian Indians living in Chennai [15]. In this study, 
the prevalence of type 2 diabetes diagnosed by HbA1c was 110% and 27% higher than the 
prevalence of type 2 diabetes as diagnosed by the fasting glucose and 2-hour post challenge 
glucose criteria respectively [15]. The current study adds to these findings by including a 
population from another city in India as well as a migrant Asian Indian population to the United 
States, thereby indicating that these findings are associated with race/ethnic background rather 
than geographical location. Furthermore, a study examining the effects of type 2 diabetes 
definition on global diabetes prevalence using a pooled analysis of 96 population-based studies 
found that while in general type 2 diabetes prevalence based on HbA1c was lower than the 
prevalence based on fasting or 2-hour plasma glucose measures , in the subgroup of studies from 
South Asia, the prevalence of type 2 diabetes based on HbA1c was higher than those based on 
fasting or 2-hour measures [16]. Similarly, a supplemental analysis of South Asians, Blacks, and 
Whites from a study in the U.K. showed that South Asians had a higher prevalence of HbA1c 
diagnosed type 2 diabetes as opposed to OGTT diagnosed type 2 diabetes when compared to 
other ethnic groups [17] thereby indicating that this particularly high type 2 diabetes prevalence 
based on the HbA1c assay may be a phenomenon unique to Asian populations. 
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  Furthermore, while  HbA1c has been shown to have high specificity but limited 
sensitivity for type 2 diabetes diagnosis in White, African American, Mexican American, and 
Brazilian populations compared to fasting and 2-hour post challenge glucose measures, [18,19], 
this may not be the case in certain Asian populations, where HbA1c may be overly sensitive with 
higher false positives.  
It is also possible that in populations of Asian Indian decent, the isolated HbA1c criteria 
for diabetes diagnosis may identify individuals with milder glucose intolerance compared to 
those diagnosed with fasting or 2-hour measures. In CARRS-2, participants with isolated HbA1c 
had significantly lower fasting and 30-minute, and 2-hour glucose measures as well as lower 
mean triglyceride, lower HOMA-IR, and higher HOMA-β and disposition index measures 
compared to those with type 2 diabetes diagnosed by fasting or 2 hour glycemia. In MASALA, 
individuals with type 2 diabetes diagnosed by isolated HbA1c had lower 2-hour glucose, total 
cholesterol, and Apo-B and higher HOMA-β compared to those with type 2 diabetes diagnosed 
by fasting or 2 hour glucose measures. In addition, they also had lower fasting and 30-minute 
glucose as well as lower HOMA-IR compared to those with type 2 diabetes diagnosed by fasting 
glucose. These results are similar to a study from Chennai, India which found that participants 
diagnosed by the HbA1c criterion had milder glucose intolerance and lower serum triglyceride 
levels than those diagnosed by fasting or 2-hour post challenge measures [15]. In aggregate, 
these findings suggest that individuals with isolated elevated HbA1c may represent either a 
different subgroup of type 2 diabetes, an earlier phase in the natural history of type 2 diabetes 
development, or a possible misdiagnosis. Furthermore, recognizing that the relationship between 
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HbA1c and glucose measures may differ by race/ethnicity has clinical relevance for minimizing 
the risks of over or under-treatment of diabetes and related complications [20].
Our study directly compared differences in type 2 diabetes prevalence by diagnostic 
criteria using two populations of Asian Indians. While there were differences in the sampling 
frames and socio-demographic characteristics between MASALA and CARRS-2, both studies 
are large population-based samples with similar laboratory and anthropometric measures and are 
representative of Asian Indians in large urban centers in India or the United States. However, the 
results of our study should be interpreted in the context of several limitations. Given that our 
study directly compares two distinct Asian Indian populations from large metropolitan cities (the 
greater San Francisco and Chicago areas of the U.S. and Chennai and Delhi India) the results 
cannot be generalized to Asian Indians living in other parts of the U.S. or India. Additional 
limitations to our study include the exclusion of participants under the age of 40 and also those 
with pre-existing cardiovascular disease.  Furthermore, the primarily cross-sectional nature of 
our study makes it impossible to determine temporality between the prevalence of type 2 
diabetes as diagnosed by isolated HbA1c and the associated covariates. Measures of insulin 
sensitivity and secretion were assessed by fasting surrogate measures, and therefore may not be 
completely accurate.  However, these results suggest milder defects in insulin secretion and 
resistance in Asian Indians diagnosed with diabetes by HbA1c compared to fasting or 2 hour 
glucose measures, and should be tested in further studies using gold-standard procedures.  In 
addition, HbA1c was measured by different methods in the CARRS and MASALA studies, 
which may possibly explain the somewhat different prevalence of diabetes diagnosed by isolated 
HbA1c in the two cohorts.  However, since that the pattern of a higher prevalence of diabetes 
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diagnosed by isolated HbA1c compared to other measures was seen in both cohorts, it is not 
likely that the different assay measures affected the overall results. HbA1c measures are also 
influenced by several conditions such as the presence of iron deficiency anemia [21].  Therefore, 
the lack of data regarding circulating iron and vitamin B12 in our study is an important 
limitation, and future studies should examine the influence of iron and B12 levels on the 
prevalence of HbA1c diagnosed diabetes in Asian Indian populations. Lastly, various factors 
such as hemoglobin variants may affect the accuracy of HbA1c measurements according to the 
assay method used [22].  Therefore knowledge and awareness of hemoglobin variants affecting 
HbA1c measurements in a given population is critical when determining whether this measure is 
appropriate as a diagnostic tool [22].     
Our findings suggest that while the prevalence of type 2 diabetes diagnosed by isolated 
elevated HbA1c is fairly low, this is still a substantial proportion of all type 2 diabetes that is 
identified by this method. Furthermore, individuals diagnosed with type 2 diabetes by isolated 
HbA1c had milder glucose intolerance, and significantly lower serum triglycerides than those 
diagnosed by fasting or 2-hour post challenge measures. While HbA1c is generally considered a 
more specific test for type 2 diabetes screening then fasting or 2 hour glucose measures, this may 
not be the case in Asian Indian individuals. Furthermore, the use of a solo test may not be the 
best strategy to diagnosed diabetes. While the combination of a 2-hour glucose test and HbA1c 
would likely capture the highest number of people with diabetes, this strategy may not be 
practical given the burdensome nature of the oral glucose tolerance test.  Given that HbA1c is 
becoming an increasingly utilized tool clinically for type 2 diabetes diagnosis, these results 
prompt the need for comprehensive studies examining the diagnostic accuracy and outcomes of 
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the different glycemic measures, particularly in Asian Indian populations. In addition, future 
longitudinal studies are needed in order to ascertain the long-term implications of a high 
prevalence of elevated isolated HbA1c on type 2 diabetes related morbidity and mortality. 
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Table 1. Age, Sex, and BMI Adjusted Prevalence of Glycemic Status in the CARRS-2 and MASALA study
CARRS-2 Chennai CARRS-2 Delhi MASALA
n 1568 1448 608
Lab diagnosis of DM n=242
18.2%
(95% CI: 15.8-20.9)
n=190 
14.0%
(95% CI: 12.0-16.4)
n=74   
12.5%
(95% CI: 9.6-16.4)
FPG ≥126 mg/dl n=136   
9.4%
(95% CI: 7.8-11.2)
n=99     
7.0%
(95% CI: 5.7-8.7)
n=19     
3.3%
(95% CI: 2.1-5.4)
PPG ≥200 mg/dl n=172  
12.3%
(95% CI: 10.5-14.5)
n=108    
 7.6%
(95% CI: 6.2-9.3)
n=63  
 11.2%
(95% CI: 8.4-14.1)
HbA1c ≥6.5% n=181
 12.9%
(95% CI: 11.0-15.1)
n=139   
9.6%
(95% CI: 8.0-11.5)
n=35    
 5.4%
(95% CI: 3.7-7.8) 
Isolated FPG ≥126 mg/dl n=10     
0.6%
n=19     
1.3%
n=0
0.0%
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(95% CI: 0.3-1.1) (95% CI: 0.8-2.1) (95% CI: 0.0-0.0)
Isolated PPG ≥200 mg/dl n=40     
2.7%
(95% CI: 1.9-3.6)
n=26     
1.8%
(95% CI: 1.2-2.6)
n=36     
5.8%
(95% CI: 4.0-8.6)
Isolated HbA1c ≥6.5% n=47     
2.9%
(95% CI: 2.2-4.0)
n=51     
3.1%
(95% CI: 2.3-4.2)
n=8   
  0.8%
(95% CI: 0.3-1.9)
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Table 2. Age, Sex, and BMI Adjusted Participant Characteristics by Glycemic Status-CARRS-Combined Chennai and Delhi
Normal Glucose Tolerance DM by FPG     DM by  2-hr Glucose Isolated HbA1c% ≥ 6.5%
N (%) 1054 (49.9) 235 (8.2) 280 (10.0) 98 (3.0)
Age (years) 48.7 (8.1)* 50.4 (7.5)* 50.9 (8.3)* 53.6 (8.6)
Men (%) 47.2 52.3 56.6 53.4
Vegetarian Diet 28.0 20.6* 20.8* 32.3
Bachelor’s degree or higher (%) 18.7* 13.3 10.7* 20.9
Income Category  (%)
  Tertile 1 38.7* 39.0 35.8 29.4
Tertile 2 23.7 28.1 28.7 23.0
Tertile 3 37.6* 32.9* 35.1* 47.7
Physical Activity Category (MET-min/week) (%)
<600 23.8 20.7 24.4 27.5
600-4000 60.7 69.8* 65.4 56.1
4,000-8000 13.1 8.0 8.2 13.7
>=8,000 2.3 1.5 2.0 2.7
Current Smoker (%) 21.7 25.5 22.3 24.0
Blood Pressure Lowering Medication Use (%) 12.7* 15.4 18.4 20.4
Lipid Lowering Medication Use (%) 3.5 2.6 2.6 3.1
BMI, kg/m2 25.1 (0.1)* 27.5 (0.3) 27.8 (0.3) 28.3 (0.5)
Waist Circumference, cm 88.4 (0.2)* 91.0 (0.5) 91.2 (0.4) 90.8 (0.7)
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Systolic blood pressure, mmHg 128.5 (0.6) 137.2 (1.3)* 138.0 (1.1)* 130.0 (2.0)
Diastolic blood pressure, mmHg 81.9 (0.4) 86.1 (0.8)* 86.4 (0.7)* 83.0 (1.2)
Fasting glucose, mmol/L 5.0 (0.05)* 10.0 (0.07)* 9.1 (0.8)* 6.1 (0.2)
30 minute glucose, mmol/L 7.8 (0.08)* 15.6 (0.1)* 14.8 (0.1)* 10.8 (0.3)
2-hour glucose, mmol/L 5.5 (0.1)* 16.5 (0.2)* 16.8 (0.1)* 7.9 (0.4)
HbA1c, % 5.3 (0.03)* 8.1 (0.05)* 7.8 (0.04)* 6.6 (0.1)
HbA1c, mmol/L 34.6 (0.3)* 65.3 (0.5)* 61.5 (0.5)* 49.1 (1.1)
†‡Fasting Insulin, pmol/L 58.3 (0.03)* 99.6 (0.1)* 92.3 (0.1)* 84.2 (0.1)
Median (IQR) 56.2 (35.4-84.3) 114.9 (76.7-116.7) 114.8 (70.2-166.7) 103.2 (72.0-146.3)
†‡HOMA-IR 1.9 (0.03)* 5.8 (0.1)* 4.9 (0.06)* 3.3 (1.2)
Median (IQR) 1.8 (1.2-2.7) 6.2 (4.2-10.5) 5.8 (3.9-9.0) 4.1 (2.7-5.9)
†‡HOMA-β 111.3 (0.03)* 53.0 (0.1)* 60.2 (0.1)* 97.4 (0.1)
Median (IQR) 105.5 (66.6-159.3) 64.0 (36.3-96.1) 74.0 (39.4-131.2) 127.3 (78.9-164.4)
†‡Disposition Index 3.0 (0.05)* 0.3 (0.1)* 0.3 (0.1)* 1.0 (0.2)
Median (IQR) 2.8 (1.7-4.8) 0.3 (0.2-0.5) 0.3 (0.2-0.5) 0.8 (0.5-1.3)
†‡Total Cholesterol 4.6 (0.01)* 5.1 (0.01)* 5.0 (0.01)* 4.9 (0.02)
Median (IQR) 5.2 (5.1-5.3) 5.3 (5.1-5.4) 5.3 (5.1-5.4) 5.3 (5.1-5.4)
†‡HDL, mmol/L 1.1 (0.01) 1.0 (0.04) 1.0 (0.01)* 1.1 (0.07)
Median (IQR) 1.1 (1.0-1.3) 1.0 (0.9-1.2) 1.0 (0.9-1.2) 1.1 (0.9-1.2)
†‡LDL, mmol/L 2.8 (0.01)* 3.0 (0.02) 3.0 (0.02)* 2.9 (0.03)
Median (IQR) 2.8 (2.3-3.3) 3.1 (2.5-3.7) 3.0 (2.5-3.7) 3.0 (2.6-3.9)
  
25
Data are given as %, mean (SD), or †geometric mean (SD) with median and interquartile range. 
* P < 0.05 vs. isolated HbA1c ≥ 6.5. 
‡Data are from a subset that includes the Delhi site only
†‡Triglycerides, mmol/L 1.3 (0.01)* 2.0 (0.03)* 1.9 (0.3)* 1.6 (0.05) 
Median (IQR) 1.2 (0.9-1.7) 2.0 (1.3-2.8) 1.9 (1.3-2.7) 1.5 (1.2-2.1)
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Table 3. Age, Sex, and BMI Adjusted Participant Characteristics by Glycemic Status-MASALA
Normal Glucose Tolerance DM by FPG DM by 2-hr Glucose Isolated HbA1c% ≥ 6.5%
N (%) 134 (28.3) 19 (3.3) 63 (11.4) 8 (1.9)
Age (years) 51.6 (8.9) 56.3 (8.3) 55.8 (8.2) 54.5 (9.6)
Men (%) 49.4 83.5 46.1 64.5
Vegetarian Diet (%) 47.6 23.3 43.6 37.4
Bachelor’s degree or higher (%) 93.1 98.9 81.7 83.7
Income Category (%)
   <$40k 10.0* 6.2* 16.7* 48.4
$40-75k 11.1 10.4 12.2 15.4
$75-100k 12.3 18.1 12.0 0.1
>100k 66.6 65.4 59.1 36.0
Physical Activity Category 
(MET-min/week) (%)
600-4000 4.0 0 0 0
4,000-8000 36.4 32.0 29.1 13.6
>=8,000 59.5 67.8 71.3 87.6
Current Smoker (%) 3.1 3.7 1.7* 15.5
Blood Pressure Lowering 
Medication Use (%)
26.1 30.6 29.9 26.8
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Lipid Lowering Medication Use 
(%)
12.7 10.1 20.1 14.5
AHEI-2010 Component Score 70.3 (0.6) 69.6 (1.6) 69.9 (0.9) 70.1 (2.7)
BMI, kg/m2 25.2 (0.4) 27.9 (1.0) 26.9 (0.6) 27.9 (1.8)
Waist Circumference, cm 90.1 (0.6)* 93.1 (1.5) 93.1 (0.8) 97.8 (2.6)
Systolic blood pressure, mmHg 121.7 (1.5) 127.2 (3.7) 128.5 (2.0) 126.8 (6.4)
Diastolic blood pressure, mmHg 71.8 (0.9) 75.9 (2.3) 75.4 (1.3) 78.0 (3.9)
Fasting glucose, mmol/L 5.0 (0.08)* 8.4 (0.1)* 6.5 (0.1)* 5.7 (0.3)
30 minute glucose mmol/L 7.8 (0.2) 13.1 (0.4)* 11.1 (0.2)* 9.2 (0.7)
2-hour glucose, mmol/L 5.7 (0.3) 15.3 (0.6)* 13.6 (0.3)* 7.7 (1.2)
HbA1c, % 5.4 (0.05)* 7.3 (0.1) 6.5 (0.1) 6.9 (0.2)
HbA1c, mmol/L 35.8 (0.5)* 56.3 (1.2) 47.8 (0.7) 51.7 (2.3)
†Fasting Insulin, pmol/L 45.9 (0.05)* 78.8 (0.1)* 63.7 (0.07) 64.1 (0.2)
Median (IQR) 46.0 (35.0-61.0) 90.1 (56.0-132.0) 71.7 (44.7-111.0) 72.1 (50.3-83.1)
†HOMA-IR 1.7 (0.05)* 4.8 (0.1)* 3.0 (0.07) 2.7 (0.2)
Median (IQR) 1.7 (1.3-2.3) 5.5 (3.4-8.6) 3.4 (1.9-5.5) 3.1 (2.4-3.7)
†HOMA-β 108.4 (0.05)* 57.4 (0.1)* 81.4 (0.07)* 97.4 (0.2)
Median (IQR) 114.5 (76.5-154.1) 63.0 (35.4-92.6) 93.4 (59.7-126.6) 93.6 (73.0-126.2)
†Disposition Index 3.6 (0.08)* 0.3 (0.2) 0.8 (0.1) 1.0 (0.3)
Median (IQR) 3.4 (2.3-5.7) 0.3 (0.2-0.6) 0.9 (0.5-1.3) 0.8 (0.7-1.3)
†Total Cholesterol, mmol/L 4.7 (0.02) 5.2 (0.04)* 5.0 (0.02)* 4.8 (0.07)
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Data are given as %, mean (SD), or †geometric mean (SD) with median and interquartile range.
* P < 0.05 vs. isolated HbA1c ≥ 6.5.                                                                                                                                                                 
‡ Data are from a restricted sample that includes only participants with adiponectin, resistin, and visceral fat mass measurements (N=516 participants)
Median (IQR) 4.8 (4.3-5.3) 5.4 (4.5-5.9) 5.1 (4.5-5.6) 4.6 (4.3-5.2)
†HDL, mmol/L 1.3 (0.02) 1.2 (0.05) 1.2 (0.03) 1.2 (0.09)
Median (IQR) 1.3 (1.1-1.6) 1.0 (1.0-1.6) 1.2 (1.0-1.4) 1.2 (0.9-1.4)
†LDL, mmol/L 2.8 (0.02) 2.9 (0.07) 2.9 (0.04) 2.8 (0.1)
Median (IQR) 2.8 (2.4-3.4) 3.0 (2.6-3.5) 3.0 (2.6-3.4) 2.8 (3.3-2.5)
†Triglycerides, mmol/L 1.1 (0.04)* 1.8 (0.1) 1.6 (0.05) 1.4 (0.2) 
Median (IQR) 1.2 (0.8-1.5) 1.8 (1.4-2.6) 1.6 (1.3-2.1) 1.6 (1.1-1.8)
†Apo-B, g/L 0.8 (0.02) 0.9 (0.05) 0.9 (0.03) 0.8 (0.09)
Median (IQR) 0.8 (0.7-0.9) 0.9 (0.8-1.0) 0.9 (0.7-1.0) 0.8 (0.7-0.9)
†‡Adiponectin (ng/ml) 11.9 (0.06)* 8.5 (0.2) 8.2 (0.08) 7.8 (0.3)
Median (IQR) 12.9 (7.8-17.0) 6.5 (4.4-10.3) 8.5 (6.0-12.1) 7.9 (4.9-11.4)
†‡Resistin (ng/ml) 17.2 (0.07)* 19.9 (0.2)* 19.8 (0.1)* 26.7 (0.3)
Median (IQR) 18.8 (16.4-24.6) 19.6 (17.7-23.6) 18.7 (16..5-23.5) 17.7 (16.3-25.8)
Subcutaneous fat area (cm2) 229.6 (7.3) 259.2 (18.2) 251.9 (10.0) 270.3 (32.3)
‡Visceral fat area (cm2) 113.5 (4.0)* 128.6 (10.3) 130.9 (5.7) 146.7 (17.1)
‡Hepatic fat attenuation (HU) 59.4 (0.9) 51.8 (2.3) 50.8 (1.3) 54.4 (3.9)
‡Pericardial fat volume (cm3) 49.2 (2.1) 63.1 (5.4) 61.8 (3.0) 52.6 (9.0)
‡Intramuscular fat area (cm2) 19.6 (0.7) 16.4 (1.9) 20.1 (1.1) 23.5 (3.1)
‡Total lean mass area (cm2) 91.0 (1.5) 92.2 (3.9) 93.6 (2.2) 86.7 (6.4)
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Figure 1.  Proportion of diabetes diagnosed by glycemic measure and study site.
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Figure legend:  A: CARRS-2, Chennai; B:  CARRS-2, Delhi; C: MASALA
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Highlights:
 Hemoglobin A1c is becoming a widely used tool for identifying type 2 diabetes.
 However, Hemoglobin A1c may not accurately identify diabetes cases in all populations.
 In South Asians, Hemoglobin A1c identifies a substantially higher proportion of individuals with diabetes compared to fasting 
or two hour measures.
 Hemoglobin A1c also identified individuals with milder cardio-metabolic risk, lower triglyceride, and lower glucose levels.  
 Future longitudinal studies are needed in order to ascertain the long-term implications of a high prevalence of elevated isolated 
HbA1c on type 2 diabetes related morbidity and mortality. 
